Contrarily, in the case of MI, (KDR+CD133+, CD133+KDR−) EPCs could be altered (in vitro) to, e.g., express higher levels of proangiogenic factors and readministered to MI patients to aid in tissue recovery. The gene discussed is PROM1; the disease is myocardial infarction.